drugset / Trial / NCT05991401

Evaluate the Effect of Clarithromycin/Rifampicin on the Pharmacokinetics of DA-8010 in Healthy Adults

NCT05991401

Phase 1 Completed 18 enrolled Dong-A ST Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, fixed-sequence, phase 1 study to evaluate the effect of clarithromycin/rifampicin on the pharmacokinetics of DA-8010 in healthy adults.

Timeline

Start
2023-08-18
Primary completion
2023-11-06
Completion
2023-11-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Clarithromycin Small molecule 500 mg
Subject Rifampin Small molecule 600 mg
Subject VELUFENACIN Small molecule 5 mg

Indications

No indication recorded.